BUZZ-Monte Rosa Therapeutics 因與諾華達成許可協議而大漲

Reuters

2024/10/28

((自動化翻譯由路透提供，請見免責聲明 ))

10月28日 - ** 藥物開發商 Monte Rosa Therapeutics 股價上漲 37.22% 至 6.84 美元 * (link) * 諾華將向 GLUE 支付 1.5 億美元的預付款，以獲得開發、生產和銷售某些候選藥物的全球許可。

** GLUE 還將有資格獲得未來高達 21 億美元的開發、監管和銷售里程碑付款

** 該協議有望加速 MRT-6160 的開發，MRT-6160 正處於免疫介導疾病的早期研究階段。

** GLUE 的股價今年以來上漲了約 20

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2478044489"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2478044489\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2478044489?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-10-28 21:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478044489","market":"us","top_or_hot":-1,"title":"BUZZ-Monte Rosa Therapeutics 因與諾華達成許可協議而大漲","media":"Reuters","content":"<html><body><p>((自動化翻譯由路透提供，請見免責聲明 ))</p><p>    10月28日 - ** 藥物開發商 <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a>   股價上漲 37.22% 至 6.84 美元 * (link) * <a href=\"https://laohu8.com/S/NVS\">諾華</a>  將向 GLUE 支付 1.5 億美元的預付款，以獲得開發、生產和銷售某些候選藥物的全球許可。</p><p>** GLUE 還將有資格獲得未來高達 21 億美元的開發、監管和銷售里程碑付款</p><p>** 該協議有望加速 MRT-6160 的開發，MRT-6160 正處於免疫介導疾病的早期研究階段。</p><p>** GLUE 的股價今年以來上漲了約 20 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Monte Rosa Therapeutics 因與諾華達成許可協議而大漲</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Monte Rosa Therapeutics 因與諾華達成許可協議而大漲\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2024-10-28 21:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>((自動化翻譯由路透提供，請見免責聲明 ))</p><p>    10月28日 - ** 藥物開發商 <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a>   股價上漲 37.22% 至 6.84 美元 * (link) * <a href=\"https://laohu8.com/S/NVS\">諾華</a>  將向 GLUE 支付 1.5 億美元的預付款，以獲得開發、生產和銷售某些候選藥物的全球許可。</p><p>** GLUE 還將有資格獲得未來高達 21 億美元的開發、監管和銷售里程碑付款</p><p>** 該協議有望加速 MRT-6160 的開發，MRT-6160 正處於免疫介導疾病的早期研究階段。</p><p>** GLUE 的股價今年以來上漲了約 20 </p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B4R5TH58.HKD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2478044489","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478044489","pubTimestamp":1730123928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自動化翻譯由路透提供，請見免責聲明 ))    10月28日 - ** 藥物開發商 Monte Rosa Therapeutics   股價上漲 37.22% 至 6.84 美元 * (link) * 諾華  將向 GLUE 支付 1.5 億美元的預付款，以獲得開發、生產和銷售某些候選藥物的全球許可。** GLUE 還將有資格獲得未來高達 21 億美元的開發、監管和銷售里程碑付款** 該協議有望加速 MRT-6160 的開發，MRT-6160 正處於免疫介導疾病的早期研究階段。** GLUE 的股價今年以來上漲了約 20","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LENZ":"Therapeutics","BK4007":"制药","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","BK4588":"碎股","NVS":"诺华","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4539":"次新股","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4578":"CAR-T","BK4139":"生物科技","GLUE":"Monte Rosa Therapeutics","BK4532":"文艺复兴科技持仓"},"translate_title":"BUZZ-Monte Rosa Therapeutics jumps on licensing deal with Novartis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"NVS":1,"GLUE":1},"content_text":"((自動化翻譯由路透提供，請見免責聲明 ))    10月28日 - ** 藥物開發商 Monte Rosa Therapeutics   股價上漲 37.22% 至 6.84 美元 * (link) * 諾華  將向 GLUE 支付 1.5 億美元的預付款，以獲得開發、生產和銷售某些候選藥物的全球許可。** GLUE 還將有資格獲得未來高達 21 億美元的開發、監管和銷售里程碑付款** 該協議有望加速 MRT-6160 的開發，MRT-6160 正處於免疫介導疾病的早期研究階段。** GLUE 的股價今年以來上漲了約 20","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}